Search details
1.
Cycling cancer persister cells arise from lineages with distinct programs.
Nature
; 596(7873): 576-582, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34381210
2.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med
; 386(12): 1143-1154, 2022 03 24.
Article
in English
| MEDLINE | ID: mdl-35320644
3.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Article
in English
| MEDLINE | ID: mdl-36495879
4.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Article
in English
| MEDLINE | ID: mdl-33882206
5.
Type I interferons, inflammation, and fatigue in a longitudinal RNA study of women with breast cancer.
Brain Behav Immun
; 118: 312-317, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38325563
6.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol
; 24(9): 1029-1041, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37657462
7.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
Breast Cancer Res
; 25(1): 2, 2023 01 11.
Article
in English
| MEDLINE | ID: mdl-36631725
8.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Article
in English
| MEDLINE | ID: mdl-31825192
9.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Article
in English
| MEDLINE | ID: mdl-31825569
10.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
J Natl Compr Canc Netw
; 21(6): 594-608, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37308117
11.
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
Cancer
; 128 Suppl 11: 2209-2223, 2022 06 01.
Article
in English
| MEDLINE | ID: mdl-35536015
12.
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 195(2): 127-139, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35545724
13.
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(6): 691-722, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35714673
14.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Future Oncol
; 18(32): 3563-3572, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36382554
15.
Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer.
Cancer
; 127(8): 1334-1344, 2021 04 15.
Article
in English
| MEDLINE | ID: mdl-33606273
16.
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Oncologist
; 26(8): e1327-e1338, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34028126
17.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med
; 379(8): 753-763, 2018 08 23.
Article
in English
| MEDLINE | ID: mdl-30110579
18.
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
Breast Cancer Res Treat
; 190(3): 357-372, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34533681
19.
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Breast Cancer Res Treat
; 188(1): 179-190, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33641083
20.
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Breast Cancer Res Treat
; 188(2): 449-458, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33909203